Influenza antivirals currently in late-phase clinical trial. - Wikidata - awgldk - TriplyDB

Influenza antivirals currently in late-phase clinical trial.

Influenza antivirals currently in late-phase clinical trial.

http://www.wikidata.org/entity/Q30398099

about

Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance.Inhibition of vaccinia virus replication by nitazoxanide.The Global Influenza Surveillance and Response System (GISRS) - A Future Perspective.Favipiravir (T-705) protects against Nipah virus infection in the hamster model.Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview Investigating Different Mechanisms of Action in Combination Therapy for Influenza

P2860

Q40051127-7CBC78C3-0762-45DD-B69C-35FA184358F7 Q51783651-F9F1E577-BE80-4092-8E1A-C393DF0B049C Q54117207-29D73C1B-2438-405B-A3F8-73410E25BE52 Q54222152-EDFE57E6-6F99-45C7-99DE-C997F87DB195 Q54989893-D691FA39-AA89-4884-BE12-13E63763A3D1 Q56985884-4276CB36-A5C1-439F-ABCC-28D42E4C4AB8 Q57093653-CFD98158-364E-4894-96D7-BF70C5260262 Q58573517-C8A8618F-0D35-4E03-A2D1-6417FD9665DA

P2860

Influenza antivirals currently in late-phase clinical trial.

http://www.wikidata.org/entity/Q30398099

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Influenza antivirals currently in late-phase clinical trial.

@ast

Influenza antivirals currently in late-phase clinical trial.

@en

type

label

Influenza antivirals currently in late-phase clinical trial.

@ast

Influenza antivirals currently in late-phase clinical trial.

@en

prefLabel

Influenza antivirals currently in late-phase clinical trial.

@ast

Influenza antivirals currently in late-phase clinical trial.

@en

P1433

Q30398099-C50747F2-1BB4-4068-9AD8-9B6AA51B5243

P1476

Q30398099-C9304393-9B49-4AE8-B79C-07132E409F32

P2093

Q30398099-57C2E2CF-0445-4EE0-8A9B-BC75A59D335B

Q30398099-92EA46CB-A3B8-46AB-8CE7-FE831F757D9B

P275

Q30398099-E044EE77-6A90-4287-B7C5-6F8C312CA883

P2860

Q30398099-013A1F30-4D23-40EE-B821-EB958BB643FE

Q30398099-02CEEA3D-BCBC-4B9D-BC53-741FD2141A79

Q30398099-04C91FDC-BABF-4542-96E0-D74B7171191D

Q30398099-08814A3F-0EF6-47F5-B8FB-03D6D36C62BA

Q30398099-088A9E00-8A29-4CBD-844F-D0ED8FF93059

Q30398099-0A264DFF-D3C7-41D5-BB46-A52974B6E84C

Q30398099-1F75236B-8E1D-4B7D-A05D-EA81392B8D72

Q30398099-21E49962-A8D0-4EC7-98F4-9AB2DBC4CF50

Q30398099-29C896D7-A6FE-4C35-9EAB-FBB6080CC039

Q30398099-2AB49AFC-4722-4F81-AD00-6EF1E82E63C9

P304

Q30398099-15157873-B19C-4D1D-94EA-08C0AFC7D231

P31

Q30398099-1BC09544-D1BF-4C0B-A8F0-8CD64656F06F

Q30398099-7973AD6D-9DC7-41DC-8433-748FDE40313A

P356

Q30398099-034C1D03-4A86-494A-ADF7-24345F5CBB9F

P433

Q30398099-3C68365D-1196-4255-B087-0B61DC300F37

P478

Q30398099-945BF04B-8F7C-4F70-AF18-E38FCF864639

P50

Q30398099-1FBFD267-46C0-4315-9C98-495146C5E9A5

P5008

Q30398099-98FFE31F-48B6-4800-BAAE-E12F8FA3A65D

P577

Q30398099-0467925E-83F1-4715-AAA7-99DCC4F70F3C

Q30398099-E0A9D385-4CE7-4E94-B299-34290FF2D29A

P698

Q30398099-1C56247F-71D8-4BCC-B101-A00CCBDC185D

P921

Q30398099-01D3B74E-A9CA-4403-8261-4185D17D3A29

Q30398099-11B2DAC4-1AB4-4673-B78B-62C2BDF74BF1

P932

Q30398099-C2530BBE-65DA-4AF5-B8F5-533816FFCEB4

P356

P1433

Influenza and Other Respiratory Viruses

P1476

Influenza antivirals currently in late-phase clinical trial.

@en

P2093

Danielle Tilmanis

http://www.w3.org/2001/XMLSchema#string

Paulina Koszalka

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

A highly conserved neutralizing epitope on group 2 influenza A viruses

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2

A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription.

Widespread use of neuraminidase inhibitors in Japan

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

P304

240-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IRV.12446

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28146320

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

5410715

http://www.w3.org/2001/XMLSchema#string